To determine the optimum bile acid regimen for rapid gail stone dissolution, 48 gall stone patients were divided into four groups of 12 according to stone diameter and were randomly allocated to receive one of four treatment regimens: bedtime or mealtime chenodeoxycholic acid (CDCA, 12 mg/kg/day) and bedtime or mealtime ursodeoxycholic acid (UDCA, 12 mg/kg/day). An additional 10 patients treated with a combination of CDCA plus UDCA (each 6 mg/kg/day) at bedtime were matched with the 10 patients on bedtime CDCA and the 10 on bedtime UDCA. The gall stone dissolution rates at six and 12 months were determined by standardised oral cholecystography and expressed as the percentage reduction in the gall stone volume after treatment. The gall stone dissolution rate at six months was higher for UDCA than CDCA treatment (median 78% v 48%, p<001), and for bedtime than mealtime administration (69% v 39%, p<002). Both differences were greater for stones <8 mm diameter. The dissolution rate was faster for combination therapy than for CDCA alone at both six (82% v 36%, p<0O05) and 12 months (100% v 54%, p<005), but was not different from UDCA alone. We conclude that bile acid treatment should be confined to patients with smail gail stones and that bedtime administration of combined UDCA and CDCA is likely to provide the most effective and safe combination.
Since the introduction of chenodeoxycholic acid (CDCA) in the early 70s" and ursodeoxycholic acid (UDCA) in the late 70s,35 many controlled and uncontrolled trials have been carried out to assess the efficacy of the two bile acids in terms of the proportion of gall stones for which complete or partial dissolution is achieved over a defined time interval. Available data suggest that the overall efficacy is similar; both bile acids achieve complete dissolution in 10-60% of patients and partial dissolution in another 10-45% of patients."3' The wide variation in the response rate can be attributed to differences in the dose of bile acid used, in treatment length, and in patient's weight in relation to ideal body weight and to different approaches to the inclusion of 'dropouts' in the final analysis. Only three controlled studies have directly compared CDCA withUDCA, and each reported that UDCA had a slight though not significant advantage over CDCA.'82228 A recent study has reported that a combination of CDCA plus UDCA is more effective than UDCA alone. 32 We have also shown that bedtime administration of CDCA is more effective than mealtime administration in improving the gall stone dissolution rate. 33 Previous studies have expressed their results in terms of the percentage of patients who achieve partial or complete gall stone dissolution, or both, within a defined time.22-24 26 28 12 34 The disadvantage ofthese studies is that only those patients who achieved complete dissolution are used for statistical analysis, and therefore there is a requirement for large numbers of patients to be enrolled, or for long periods of treatment follow up. This has prevented the demonstration of clearcut differences between the two bile acids. We have previously developed and validated a standard oral cholecystographic technique35 for measurement of the gall stone dissolution rate, defined as the percentage reduction in gall stone volume at predetermined intervals after the start of treatment. This measurement is quantitative and allows the use of all patients data in a trial of dissolution treatment.
The aims of the present study were as follows: stone volume after treatment) for all patients is given in Table II .
GALLSTONE DISSOLUTION RATE: EXPERIMENT I
Effect ofindividual bile acids UDCA treatment resulted in a significantly greater gall stone dissolution rate than CDCA at six months (n=24, median 78% v 48%, p<0 01), but the difference between the two bile acids was smaller and no longer significant at 12 months (90% v 74%, NS). For small stones (Fig 1) , the gall stone dissolution rate was significantly faster during UDCA than CDCA treatment at six months (90% v 55%, p<0 001, n= 12) , and also at 12 months (95% v 90%, p<001). By contrast, for large stones there was no difference between the two bile acids at six or 12 months (52% v 25%, NS, n=12; and 69% v 51%, NS, n=12 respectively).
Effect ofdose timing Pooling the results for both bile acids, the gall stone dissolution rate was higher for bedtime than mealtime administration at six months (69% v 49%, p<0 02, n=24). The difference between the two dose times was no longer significant at 12 months (91% v 77%, NS, n=24).
The gall stone dissolution rate for small stones was significantly higher for bedtime than mealtime administration both at six months (90% v 55% p<0 005, n=12) and 12 months (100% v 85%, p<0005, n=12; Fig 2) . By contrast, there was no difference between six and 12 month gall stone dissolution rate for mealtime and bedtime administration in patients with large stones (35% v 37%, NS (n= 12) and 51% v 58%, NS (n= 12) respectively (Fig 2) .
When the two bile acids are compared in terms of dose timing, UDCA was found to be more effective than CDCA for both mealtime and bedtime administration (83% v 47%, p<001 However, when the cumulative decrease in diameter during CDCA treatment was plotted against that for matched stones on UDCA, most of the data points were above the identity line at both six and 12 months (Figs 3A and 3B) indicating that although the gall stone dissolution rate during UDCA decreased during the second six-month period compared with the first, it remained quantitatively higher than for CDCA during both periods.
EXPERIMENT II Effect ofcombination treatment (Fig 4) Combination treatment given at bedtime was more effective than bedtime CDCA after six months (82% v 36%, p<0 05) and 12 months of treatment (100% v 54%, p<0 05). However, there was no difference between combination therapy and UDCA at six months (82% v 85%, NS) or at 12 months (100% v 93%, NS, Fig 4) .
PATIENTS ACHIEVING PARTIAL AND COMPLETE GALL STONE DISSOLUTION
Both UDCA and combination treatment showed a trend towards higher total (partial and complete) dissolution rates than CDCA at six months (70% and 60% on combination therapy and UDCA respectively, compared with 45% on CDCA). This trend was mainly due to a higher complete gall stone dissolution rate, with similar partial dissolution rates for all three regimens. There was no difference between the regimens at 12 months.
Dissolution failure at six months (0% dissolution rate), and arrested dissolution (no change in dissolution rate between six and 12 months) were found in 5/24 patients on CDCA, 7/24 patients on UDCA, and 3/10 patients on combination therapy. There was no significant difference between the three groups in this respect.
Discussion
In this study, we have combined two approaches in order to determine, in a controlled manner, the most effective oral treatment Figure 1 ). This is compared with bedtime chenodeoxycholic acid and with bedtime ursodeoxycholic acid alone.
(each containing 12 patients), into two equal groups of six with large or small stones. The issue of gall stone size has become of great importance in recent years since the establishment of extracorporeal shockwave lithotripsy (ESWL) as a non-surgical treatment option for cholesterol gall stones. 39 ESWL converts large stones into small fragments which then have to be dissolved by oral bile acid therapy. This, coupled with the fact that very large stones are unsuitable for bile acid therapy,'535 has modified the role of bile acid therapy for gall stone treatment. Our comparisons for small stones should apply also for small stone fragments after ESWL.
Our results show that UDCA was more effective than CDCA at six months but that the difference disappeared at 12 months (Fig 1) (Fig  1) , we found that for small stones UDCA had a higher efficacy than CDCA at six months (90% v 55%) and that this was still present at 12 months, whereas for large stones there was no difference between the two bile acids even at six months. However, when the reduction in diameter for CDCA was compared with that for UDCA (Fig  3) , we found a larger reduction in diameter for UDCA than CDCA both at six and 12 months.
The finding that a similar proportion of patients on CDCA and UDCA showed no dissolution (0% dissolution rate) or arrested dissolution suggests that acquired calcification does not play a major role. Since computed tomography was not performed before treatment, we cannot state whether failure of dissolution was due to subradiological calcification or to radiolucent non-cholesterol stones. However, 7/8 patients with radiolucent stones on oral cholecystography who had failed or arrested dissolution had calcification on computed tomogram. This suggests that computed tomographic scanning may be an important factor in selecting patients for bile acid treatrnent.
In assessinig the effect of dose timing, regardless ofthe type of bile acid, we found a higher gall stone dissolution rate for bedtime than mealtime admiinistrationi at six but not 12 months. The eftect of bedtime administration was more pronounced for small stones with the difference persisting at 12 months (Fig 2) . When lution at six months and 100% at 12 months).
For combination therapy, the reason for using equal doses (6 mg/kg/day) of CDCA and UDCA was to determine whether combination treatment has an additive effect (in which case its efficacy should lie between that of CDCA and UDCA in the full monotherapeutic dose) or whether it has a synergistic effect (in which case it should have a higher efficacy than either of the other two bile acids given alone). Our results suggest the latter. A comparison of three groups of patients with matched gall stones showed that combination treatment at bedtime achieved a dissolution rate at six months that was significantly higher than for bedtime CDCA, but not higher than for bedtime UDCA. These results do not confirm those of Podda et al,32 who reported, in a much larger group ofpatients, that combination treatment was significantly better than UDCA in achieving complete gall stone dissolution, but extend Podda's study by showing that combination therapy is significantly better than CDCA (Fig 4) .
We conclude that bile acid treatment should be confined to patients with small gall stones (or small fragments after ESWL). Bedtime administration is more effective than that at mealtime for CDCA, but UDCA is more effective than CDCA. Combination treatment is more effective than CDCA alone, although we could not confirm its superiority over UDCA alone.
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